8:12 AM
Mar 30, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AIT reports Phase II data for lung infection candidate

AIT Therapeutics Inc. (Pink:AITB) reported data from nine patients with non-tuberculosis Mycobacterial (NTM) infections in the Phase II NO-NTM Abscessus trial showing that AIT-NTM for 21 days led to a mean reduction in Mycobacterium abscessus load from baseline to day 81 of 65%. The...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >